-

Adagio Medical to Participate at the TD Cowen's 45th Annual Health Care Conference

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that management will be attending TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at the Marriott Copley Place in Boston, MA.

About Adagio Medical

Adagio Medical is an early commercial stage medical device company located in Laguna Hills, California focusing on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia.

Contacts

Media:
Ilya Grigorov
Vice President, Global Marketing and Product Management of Adagio Medical, Inc.
igrigorov@adagiomedical.com

Investor:
IR@adagiomedical.com

Industry:

Adagio Medical Holdings, Inc.

NASDAQ:ADGM
Release Versions
English

Contacts

Media:
Ilya Grigorov
Vice President, Global Marketing and Product Management of Adagio Medical, Inc.
igrigorov@adagiomedical.com

Investor:
IR@adagiomedical.com

More News From Adagio Medical Holdings, Inc.

Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufacturing and Operations. “These appointments represent a significant milestone as Adagio prepares for commercializat...

Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company’s Audit Committee and Compensation Committee. Mr. Salmon, 60, recently retired from Medtronic after a distinguished, 20+ year tenure during which he held multiple senior...

Adagio Medical Reports Third Quarter 2025 Results

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of app...
Back to Newsroom